Related Experiment Video
Updated: Sep 19, 2025
Use of a Piglet Model for the Study of Anesthetic-induced Developmental Neurotoxicity AIDN: A Translational Neuroscience Approach
Published on: June 11, 2017
Pentazocine Pharmacodynamics in Children: Simulations to Assess Safety and Effectiveness
Takayuki Omori1,2,3, Takahiko Aoyama2, Yasuhiro Tsuji2
1Department of Pharmacy, St. Luke's International Hospital, Tokyo, Japan.
Insights
A 6-hour dosing interval for pentazocine (0.5 mg/kg) in children balances effective pain relief with reduced risk of respiratory depression. This interval is recommended, especially considering potential decreases in drug clearance.
Area of Science:
- Pharmacology
- Pediatric Anesthesiology
- Clinical Pharmacokinetics
Background:
- Pentazocine is utilized for postoperative pain management but carries a risk of respiratory depression.
- Pediatric hepatic metabolic activity approaches adult levels, yet the impact of multiple pentazocine doses on children with reduced drug clearance remains unclear.
Purpose of the Study:
- To evaluate pentazocine-induced respiratory depression using a pharmacokinetic-pharmacodynamic (PK-PD) model.
- To determine an optimal dosing frequency for maintaining therapeutic pentazocine concentrations for analgesia in children.
Main Methods:
- A three-compartment pharmacokinetic model was employed, with pharmacodynamic parameters estimated via sequential analysis.
- Respiratory rate and oxygen saturation data were analyzed using a turnover model, linking plasma pentazocine concentration to respiratory function.
- Simulations explored various dosing intervals (2, 4, 6 hours) and reduced clearance scenarios (20%, 40%).
Main Results:
- Single pentazocine doses caused a delayed decrease in respiratory rate, returning to baseline within approximately 75 minutes.
- Multiple 2-hour dosing intervals led to significant reductions in respiratory rate and oxygen saturation, irrespective of clearance.
- A 6-hour interval demonstrated minimal respiratory depression, while effectively controlling pain across all simulated intervals.
Conclusions:
- Pharmacokinetic-pharmacodynamic modeling supports a 6-hour dosing interval for pentazocine (0.5 mg/kg) in pediatric patients.
- This dosing regimen effectively manages pain while mitigating the risk of respiratory depression.
- The findings are crucial for optimizing pentazocine use in children, particularly those with potentially impaired drug clearance.
Background:
Pentazocine is used for postoperative pain but is known to cause respiratory depression. Although hepatic metabolic activity in children gradually reaches adult levels, the effect of multiple doses in children with decreased clearance has not been elucidated.
Aims:
The objective of this study is to evaluate respiratory depression caused by pentazocine using a pharmacokinetic-pharmacodynamic model and to optimize the dosing frequency to maintain target concentrations for analgesia.
Methods:
The pharmacokinetic model used the parameters of the three-compartment model reported by Hamunen et al. Pharmacodynamic parameters were estimated through sequential analysis, with the pharmacokinetic parameters fixed. Mean respiratory rate and oxygen saturation data were collected from Hamunen et al. after the administration of 0.5 mg/kg pentazocine. The pharmacodynamic model was a turnover model in which the plasma pentazocine concentration affected the respiratory rate and oxygen saturation. We used the pharmacokinetic-pharmacodynamic model to simulate changes in respiratory rate and oxygen saturation after 0.5 mg/kg pentazocine at 2-, 4-, and 6-h dosing intervals. We also simulated cases with 20% and 40% decreased clearance. Pain relief was assessed using our previous model.
Results:
After a single dose, respiratory rate dropped with a delayed response to the plasma concentration, reaching a minimum within 15 to 30 min and falling below the normal range. It returned to baseline after about 75 min. With multiple dosing, respiratory rate and oxygen saturation considerably decreased every 2 h, regardless of clearance changes. At a 4-h interval, respiratory depression occurred due to decreased clearance, whereas at a 6-h interval, it was minimal. Pain was well controlled at 2-, 4-, and 6-h dosing intervals.
Conclusions:
This pharmacokinetic-pharmacodynamic modeling study supports a 6-h dosing interval for pentazocine at 0.5 mg/kg in children. This interval strikes a balance between achieving effective analgesia and minimizing the risk of respiratory depression.
Related Concept Videos
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
01:21Factors Affecting Drug Response: Overview
01:24Parenteral Anesthetics: Overview
01:19Depolarizing Blockers: Pharmocokinetics